Infliximab and Adalimumab in Irritable Bowel Disease Patients.

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rehab Werida
• Treatments: Adalimumab; Infliximab

Criteria

Inclusion Criteria:

1. Adult patients between 18 years and 80 years.

2. Patients having moderate to severe IBD according to European Crohn's and colitis organization (ECCO) guidelines.

3. IBD patients receiving either IFX or ADA.

Exclusion Criteria:

1. Patients missed one-year follow-up or with missed data.

2. Patients having mild IBD according to ECCO guidelines.

3. Patients having any of the Contraindications to the biological Therapy e.g.: latent TB, viral or fungal or bacterial infection.